Cargando…
Mapping heterogeneity in glucose uptake in metastatic melanoma using quantitative (18)F-FDG PET/CT analysis
BACKGROUND: Metastatic melanoma patients can have durable responses to systemic therapy and even long-term survival. However, a large subgroup of patients does not benefit. Tumour metabolic alterations may well be involved in the efficacy of both targeted and immunotherapy. Knowledge on in vivo tumo...
Autores principales: | de Heer, Ellen C., Brouwers, Adrienne H., Boellaard, Ronald, Sluiter, Wim J., Diercks, Gilles F. H., Hospers, Geke A. P., de Vries, Elisabeth G. E., Jalving, Mathilde |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6246760/ https://www.ncbi.nlm.nih.gov/pubmed/30460579 http://dx.doi.org/10.1186/s13550-018-0453-x |
Ejemplares similares
-
Clinically feasible semi-automatic workflows for measuring metabolically active tumour volume in metastatic melanoma
por: van Sluis, Joyce, et al.
Publicado: (2020) -
(18)F-FDG PET/CT Scans Can Identify Sub-Groups of NSCLC Patients with High Glucose Uptake in the Majority of Their Tumor Lesions
por: Hendriks, Anne M., et al.
Publicado: (2021) -
Preoperative BRAF inhibition in patients with irresectable locally advanced stage III melanoma
por: Faut, Marloes, et al.
Publicado: (2018) -
PET segmentation of bulky tumors: Strategies and workflows to improve inter-observer variability
por: Pfaehler, Elisabeth, et al.
Publicado: (2020) -
Manual Versus Artificial Intelligence-Based Segmentations as a Pre-processing Step in Whole-body PET Dosimetry Calculations
por: van Sluis, Joyce, et al.
Publicado: (2022)